SAB Biotherapeutics (SABS) Long-Term Debt Repayments (2022 - 2025)
SAB Biotherapeutics (SABS) reported Long-Term Debt Repayments of $3.0 for Q3 2025, down 100.0% on a YoY basis from $615818.0 in Q3 2024, and down 100.0% quarter-over-quarter from $138551.0 in Q2 2025.
SAB Biotherapeutics (SABS) Long-Term Debt Repayments (2022 - 2025) Analysis & Trends
SAB Biotherapeutics has reported Long-Term Debt Repayments for 4 years, with the latest figure at $3.0 in Q3 2025.
- For the quarter ending Q3 2025, Long-Term Debt Repayments fell 100.0% year-over-year to $3.0; the trailing twelve-month figure through Dec 2025 stood at $275849.0 (down 78.63% YoY), and the FY2025 full-year result was $275849.0, down 78.63% from the prior year.
- Long-Term Debt Repayments for Q3 2025 stood at $3.0, down from $138551.0 in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $761050.0 in Q2 2022, with the low at $3.0 in Q3 2025.
- Historically, Long-Term Debt Repayments has averaged $323711.2 across 4 years, with a median of $254913.0 in 2022.
- Annual changes were most pronounced in 2024 — Long-Term Debt Repayments surged 450.36% — and 2025, when it sank 100.0%.
- SAB Biotherapeutics' Long-Term Debt Repayments stood at $488437.0 in 2022, then sank by 47.59% to $255989.0 in 2023, then decreased by 6.19% to $240133.0 in 2024, then slumped by 100.0% to $3.0 in 2025.
- The last three Long-Term Debt Repayments figures came in at $3.0 (Q3 2025), $138551.0 (Q2 2025), and $137295.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.00 |
| Sep 30, 2025 | 3.00 |
| Jun 30, 2025 | 138,551.00 |
| Jun 30, 2025 | 138,551.00 |
| Mar 31, 2025 | 137,295.00 |
| Mar 31, 2025 | 137,295.00 |
| Dec 31, 2024 | 240,133.00 |
| Dec 31, 2024 | 240,133.00 |
| Sep 30, 2024 | 615,818.00 |
| Sep 30, 2024 | 615,818.00 |
| Jun 30, 2024 | 219,649.00 |
| Jun 30, 2024 | 219,649.00 |
| Mar 31, 2024 | 215,382.00 |
| Mar 31, 2024 | 215,382.00 |
| Dec 31, 2023 | 255,989.00 |
| Dec 31, 2023 | 255,989.00 |
| Sep 30, 2023 | 111,893.00 |
| Sep 30, 2023 | 111,893.00 |
| Jun 30, 2023 | 332,585.00 |
| Jun 30, 2023 | 332,585.00 |